LifeLab selected Transgenomic Inc.'s (Nasdaq: TBIO) ICE COLD-PCR technology as its mutation enrichment platform for cancer testing but the stock price fell as investors locked in profits.
Profit taking weighs down shares of Transgenomic
January 13, 2017 at 17:38 PM EST